Deferiprone Lipomed (deferiprone)
- Region
- 🇪🇺 EU
- Active substance
- deferiprone
- Company
- Lipomed GmbH
- Status
- Authorised
- Therapeutic area
- Iron Overload; beta-Thalassemia
- CHMP opinion
- Thu 26 Jul 2018
- EU approval
- Wed 19 Sep 2018
- Designations
- Generic
- Application
- EMEA/H/C/004710
- ATC
- V03AC02
- Official record
- www.ema.europa.eu
Indication
Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ferriprox Authorised · Chiesi Farmaceutici S.p.A.
- 🇪🇺 Upkanz Application withdrawn · Apotex B.V.
Follow Deferiprone Lipomed
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.